tiprankstipranks
Terns Pharmaceuticals reports Q3 EPS (44c), consensus (52c)
The Fly

Terns Pharmaceuticals reports Q3 EPS (44c), consensus (52c)

As of September 30, cash, cash equivalents and marketable securities were $187.3M as compared with $166M as of December 31, 2021. The company said, "The third quarter marked an exciting period for Terns, as we continued to accelerate development of our three lead programs in indications with large unmet need. With the completion of our $65 million financing in August, we are well-positioned to advance TERN-701 in CML and TERN-601 in obesity into the clinic in the United States in 2023. We also look forward to top-line data from the Phase 2a DUET trial evaluating TERN-501 monotherapy and in combination with TERN-101, the first trial to assess both THR-beta and FXR agonists in NASH, in the second half of 2023. We look forward to continued momentum in 2023 and multiple important milestones for Terns’ product candidates next year."

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on TERN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles